July 23, 2017 4:02 PM ET

Pharmaceuticals

Company Overview of TaiGen Biotechnology Co., Ltd.

Company Overview

TaiGen Biotechnology Co., Ltd., a pharmaceutical company, engages in the development of novel therapeutics for infectious diseases, cancer, and diabetes. Its products include Nemonoxacina, a drug-resistant anti-infection drug for community acquired pneumonia, diabetic foot infection, skin infections, and nosocomial pneumonia; Taigexyn, a non-fluorinated quinolone antibiotic; and stem cell mobilizer products to mobilize stem cells and progenitor cells from the bone marrow into peripheral circulation, as well as for chemosensitization treatment of leukemia patients. The company also provides hepatitis C virus protease inhibitors, anti-influenza drugs, anti-gram negative drugs, and bacteria dru...

138 Shin Ming Road

7th Floor

Neihu Dist.

Taipei,  114

Taiwan

Founded in 2001

Phone:

886 2 8177 7072

Fax:

886 2 2796 3606

Key Executives for TaiGen Biotechnology Co., Ltd.

Founder, Executive Chairman, Chief Executive Officer and President
Chief Commercial Officer - Asia, Product Development and Mktg GM Taigen Beijing Office
Senior Vice President of Business Development
Senior Director of Finance
Senior Director of Discovery Research and Chemical Development
Compensation as of Fiscal Year 2017.

TaiGen Biotechnology Co., Ltd. Key Developments

TaiGen Biotechnology Announces Submission of New Drug Application for Taigexyn® Intravenous Formulation to the China Food and Drug Administration

TaiGen Biotechnology Company, Limited announced that it has submitted a New Drug Application (NDA) for the intravenous formulation of Taigexyn® (Nemonoxacin) to the China Food and Drug Administration (CFDA). Taigexyn® is a novel non-fluorinated quinolone antibiotic. The NDA submission is supported by a pivotal Phase 3 trial comparing intravenous formulations of Taigexyn® 500 mg to levofloxacin 500 mg in 518 patients with moderate to severe community-acquired pneumonia. The clinical success rates were 91.8% for Taigexyn® vs. 85.7% for levofloxacin and Taigexyn® was shown to be non-inferior to levofloxacin meeting the primary endpoint of the pivotal trial.

TaiGen Biotechnology Company, Limited Inks Licensing Agreement with Productos Cientificos

TaiGen Biotechnology Company, Limited reported that they have signed an exclusive licensing agreement with Productos Cientificos S.A. de C.V. to develop and commercialize Taigexyn (nemonoxacin) in Latin America. Taigexyn is a novel antibiotic for the treatment of bacterial infections including those caused by drug-resistant bacteria. Under the terms of the agreement, PC will be responsible for the development, registration and commercialization of Taigexyn in the territory and assume all associated costs. The territory includes Mexico, Brazil, Colombia, Peru, Uruguay, Paraguay, Bolivia, Venezuela, Argentina, Chile, Costa Rica, Honduras, Nicaragua, Panama, Guatemala, El Salvador and Ecuador. In exchange for the exclusive rights, TaiGen will receive an upfront payment and is eligible for additional regulatory and commercial milestones in the future. PC will purchase Taigexyn at a pre-negotiated price from TaiGen for its commercialization in the territory.

TaiGen Signs Licensing Agreement with Productos Cientificos

TaiGen Biotechnology Co., Ltd. has entered into an exclusive licensing agreement with Productos Cientificos S.A. de C.V. to develop and commercialize Taigexyn(R) (nemonoxacin) in Latin America. Taigexyn(R) is a novel antibiotic for the treatment of bacterial infections including those caused by drug-resistant bacteria. Under the terms of the transaction, PC will be responsible for the development, registration and commercialization of Taigexyn(R) in the territory and assume all associated costs. The territory includes Mexico, Brazil, Colombia, Peru, Uruguay, Paraguay, Bolivia, Venezuela, Argentina, Chile, Costa Rica, Honduras, Nicaragua, Panama, Guatemala, El Salvador and Ecuador. In exchange for the exclusive rights, TaiGen will receive an upfront payment and is eligible for additional regulatory and commercial milestones in the future. PC will purchase Taigexyn(R) at a pre-negotiated price from TaiGen for its commercialization in the territory.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TaiGen Biotechnology Co., Ltd., please visit www.taigenbiotech.com.tw. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.